Trying to keep up with all that's happening in the battle against Alzheimer's disease isn't easy when you're a caregiver. The ...

A visit from "Kelvis," an Elvis impersonator, is just one of the ways residents are made to feel special at the memory care center.

Alex Yang details founding an AI startup with other high schoolers worldwide to improve Alzheimer's diagnostics.

As former Sentinel columnist George Diaz writes, Dan Jaworski is beating the odds and helping the fight against Alzheimer’s ...

LSU School of Art’s Glassell Gallery will feature the work of painters Will Maxen and Bradley Kerl, who recently joined LSU ...

Alzheimer’s is a cruel disease impacting more than 210,500 people in North Carolina. In Rowan County, 11.2 percent of residents over the age of 65 have an Alzheimer’s diagnosis. This is a deeply ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate ...

Diagnosed in 2024, Portland resident Christy Scattarella has been using her own journey with Alzheimer’s to uplift others and erase stigma surrounding the disease. She champions her “Optimist’s Guide ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo. Reading time 4 minutes Two of the most anticipated studies this ...